77 results on '"Giarratano T"'
Search Results
2. 96MO Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): A non-inferiority meta-analysis
- Author
-
Girardi, F., primary, Barbieri, C., additional, Griguolo, G., additional, Giarratano, T., additional, Miglietta, F., additional, Bottosso, M., additional, Cattelan, A.C., additional, Iannaccone, D., additional, Zurlo, C., additional, Mioranza, E., additional, Dieci, M.V., additional, and Guarneri, V., additional
- Published
- 2023
- Full Text
- View/download PDF
3. 225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments
- Author
-
Valenza, C., primary, Trapani, D., additional, Sposetti, C., additional, Bielo, L. Boscolo, additional, Marra, A., additional, Giarratano, T., additional, Cortesi, L., additional, Moscetti, L., additional, Pistelli, M., additional, Berardi, R., additional, Zambelli, A., additional, Guarneri, V., additional, Vernieri, C., additional, and Curigliano, G., additional
- Published
- 2023
- Full Text
- View/download PDF
4. The Mini-COG as Cognitive Screening Tool in Elderly Cancer Patients: A Monoistitutional, Prospective Experience at Istituto Oncologico Veneto (IOV)
- Author
-
Silvestri, G., primary, Giarratano, T., additional, Sommacal, S., additional, Mioranza, E., additional, Giorgi, C.A., additional, Serpentini, S., additional, Ronconi, L., additional, Bottosso, M., additional, Barbieri, C., additional, Guarneri, V., additional, and Falci, C., additional
- Published
- 2022
- Full Text
- View/download PDF
5. 237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
- Author
-
Brasó-Maristany, F., primary, Griguolo, G., additional, Chic, N., additional, Pare Brunet, L., additional, Galván, P., additional, Dieci, M.V., additional, Miglietta, F., additional, Giarratano, T., additional, Martínez-Sáez, O., additional, Marin, M., additional, Vidal Losada, M.J., additional, Adamo, B., additional, Munoz, M., additional, Vivancos, A., additional, Villagrasa Gonzalez, P., additional, Parker, J., additional, Perou, C.M., additional, Conte, P.F., additional, Prat, A., additional, and Guarneri, V., additional
- Published
- 2022
- Full Text
- View/download PDF
6. 26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin
- Author
-
Miglietta, F., primary, Zarrilli, G., additional, Massa, D., additional, Griguolo, G., additional, Fassan, M., additional, Bottosso, M., additional, Giorgi, C.A., additional, Giarratano, T., additional, Vernaci, G., additional, Cesarotto, M., additional, Guarascio, M.C., additional, Guarneri, V., additional, and Dieci, M.V., additional
- Published
- 2022
- Full Text
- View/download PDF
7. C14 - From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O., Cursano, M.C., De Angelis, C., Giarratano, T., Saggia, C., Beano, A., Cazzaniga, M., La Verde, N., Milani, A., Collovà, E., Coltelli, L., de Conciliis, E., Vandone, A.M., Airoldi, M., D'Onofrio, L., Bertolini, I., Guarneri, V., Donadio, M., Riva, F., and Merlano, M.C.
- Published
- 2017
- Full Text
- View/download PDF
8. C51 - Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study
- Author
-
Giarratano, T., Dieci, M.V., Guarneri, V., Grosso, D., Zanocco, M., Faggioni, G., Falci, C., Ghiotto, C., Giorgi, C.A., Griguolo, G., Mioranza, E., Pernice, G., Vernaci, G., and Conte, P.
- Published
- 2017
- Full Text
- View/download PDF
9. C20 - First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients
- Author
-
Dieci, M.V., Guarneri, V., Giarratano, T., Mion, M., Tortora, G., Morandi, P., Gori, S., Merlini, L., Oliani, C., Pasini, F., Bonciarelli, G., Griguolo, G., Orvieto, E., Del Bianco, P., De Salvo, G.L., and Conte, P.
- Published
- 2017
- Full Text
- View/download PDF
10. 129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial
- Author
-
Dieci, M.V., primary, Griguolo, G., additional, Bisagni, G., additional, Musolino, A., additional, Spazzapan, S., additional, Moretti, G., additional, Schiavi, F., additional, Pinato, C., additional, Vernaci, G.M., additional, Giarratano, T., additional, Urso, L., additional, Tosi, A., additional, Magni, G., additional, Lo Mele, M., additional, De Salvo, G.L., additional, Rosato, A., additional, Guarneri, V., additional, and Conte, P.F., additional
- Published
- 2021
- Full Text
- View/download PDF
11. 212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment
- Author
-
Miglietta, F., primary, Griguolo, G., additional, Bottosso, M., additional, Giarratano, T., additional, Lo Mele, M., additional, Fassan, M., additional, Cacciatore, M., additional, Genovesi, E., additional, De Bartolo, D., additional, Vernaci, G., additional, Amato, O., additional, Porra, F., additional, Conte, P.F., additional, Guarneri, V., additional, and Dieci, M.V., additional
- Published
- 2021
- Full Text
- View/download PDF
12. 242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
- Author
-
Miglietta, F., Dieci, M.V., Giarratano, T., Torri, V., Giuliano, M., Zustovich, F., Mion, M., Tondini, C., Bria, E., Franchi, M., Merlini, L., Giannatiempo, R., Russo, D., Fotia, V., Poletti, P., Caremoli, E. Rota, Arpino, G., De Salvo, G., Zambelli, A., and Guarneri, V.
- Published
- 2023
- Full Text
- View/download PDF
13. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- Author
-
Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E., Conte P., Frassoldati A., Bisagni G., Brandes A.A., Donadio M., Garrone O., Piacentini F., Cavanna L., Giotta F., Aieta M., Gebbia V., Molino A., Musolino A., Ferro A., Maltoni R., Danese S., Zamagni C., Rimanti A., Cagossi K., Russo A., Pronzato P., Giovanardi F., Moretti G., Lombardo L., Schirone A., Beano A., Amaducci L., Bajardi E.A., Vicini R., Balduzzi S., D'Amico R., and Guarneri V.
- Subjects
Oncology ,Time Factors ,Adjuvant, Breast cancer, Cardiac safety, De-escalated treatment, Trastuzumab ,Settore MED/06 - Oncologia Medica ,Receptor, ErbB-2 ,medicine.medical_treatment ,Anthracycline ,030204 cardiovascular system & hematology ,Breast cancer ,Antineoplastic Agents, Immunological ,ErbB-2 ,0302 clinical medicine ,Trastuzumab ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,Anthracyclines ,skin and connective tissue diseases ,Adjuvant ,Mastectomy ,Cardiac safety ,De-escalated treatment ,Hazard ratio ,Hematology ,Middle Aged ,Chemotherapy regimen ,Bridged-Ring Compound ,Immunological ,Local ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,Taxoids ,Trastuzumab, adjuvant, breast cancer, cardiac safety, de-escalated treatment ,Breast Neoplasm ,Human ,Receptor ,medicine.drug ,Adult ,Bridged-Ring Compounds ,medicine.medical_specialty ,Time Factor ,Socio-culturale ,Breast Neoplasms ,Antineoplastic Agents ,Disease-Free Survival ,Drug Administration Schedule ,03 medical and health sciences ,Taxoid ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Risk factor ,Aged ,Neoplasm Staging ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,medicine.disease ,Cardiotoxicity ,Neoplasm Recurrence ,Neoplasm Recurrence, Local ,business - Abstract
Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)
- Published
- 2018
14. Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico Del Nord Ovest) Study
- Author
-
Garrone O, Giarratano T, Blondeaux E, Mastro LD, Santini D, D’Onofrio L, Michelotti A, Landucci E, Beano A, Aprile G, Guarneri V, Paccagnella M, Vanella P, Ruatta F, Denaro N, Saggia C, Coltelli L, Allegrini G, Cazzaniga ME, LaVerde N, Collovà E, Montemurro F, Blasi L, Ardito R, DeConciliis E, Airoldi M, and Merlano MC
- Published
- 2021
15. 122P Abemaciclib in HR+/HER2- metastatic breast cancer: A real-world experience
- Author
-
Bottosso, M., primary, Giarratano, T., additional, Barbieri, C., additional, Menichetti, A., additional, Cumerlato, E., additional, Miglietta, F., additional, Genovesi, E., additional, Amato, O., additional, Dieci, M.V., additional, Griguolo, G., additional, and Guarneri, V., additional
- Published
- 2021
- Full Text
- View/download PDF
16. 4MO_PR HER2-low breast cancer: Evolution from primary breast cancer to relapse
- Author
-
Miglietta, F., primary, Griguolo, G., additional, Bottosso, M., additional, Giarratano, T., additional, Lo Mele, M., additional, Fassan, M., additional, Cacciatore, M., additional, Genovesi, E., additional, De Bartolo, D., additional, Vernaci, G., additional, Conte, P.F., additional, Guarneri, V., additional, and Dieci, M.V., additional
- Published
- 2021
- Full Text
- View/download PDF
17. 290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O., primary, Giarratano, T., additional, Michelotti, A., additional, Saggia, C., additional, D'Onofrio, L., additional, Merlini, L., additional, Blondeaux, E., additional, Beano, A., additional, Coltelli, L., additional, Cazzaniga, M.E., additional, Montemurro, F., additional, Farnesi, A., additional, La Verde, N.M., additional, Vandone, A.M., additional, Collovà, E., additional, Blasi, L., additional, Ardito, R., additional, DeConciliis, E., additional, Airoldi, M., additional, and Merlano, M.C., additional
- Published
- 2020
- Full Text
- View/download PDF
18. 162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial
- Author
-
Dieci, M.V., primary, Guarneri, V., additional, Bisagni, G., additional, Tosi, A., additional, Musolino, A., additional, Spazzapan, S., additional, Moretti, G., additional, Vernaci, G.M., additional, Giarratano, T., additional, Lo Mele, M., additional, Rosato, A., additional, De Salvo, G.L., additional, and Conte, P.F., additional
- Published
- 2020
- Full Text
- View/download PDF
19. 125P Prognostic factors in phyllodes tumours (PT) of the breast: A single-institution cohort
- Author
-
Di Liso, E., primary, Bottosso, M., additional, Tsvetkova, V., additional, Lo Mele, M., additional, Dieci, M.V., additional, Falci, C., additional, Faggioni, G., additional, Tasca, G., additional, Giorgi, C.A., additional, Giarratano, T., additional, Mioranza, E., additional, Dei Tos, A.P., additional, Guarneri, V., additional, and Conte, P.F., additional
- Published
- 2020
- Full Text
- View/download PDF
20. Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study
- Author
-
Dieci, M.V., primary, Giorgi, C.A., additional, Griguolo, G., additional, Angelini, S., additional, Miglietta, F., additional, Giarratano, T., additional, Falci, C., additional, Faggioni, G., additional, Tasca, G., additional, Mioranza, E., additional, Vernaci, G., additional, Menichetti, A., additional, Mantiero, M., additional, Genovesi, E., additional, Frezzini, S., additional, Michieletto, S., additional, Guarneri, V., additional, and Saibene, T., additional
- Published
- 2019
- Full Text
- View/download PDF
21. SIOG2022-0138 - The Mini-COG as Cognitive Screening Tool in Elderly Cancer Patients: A Monoistitutional, Prospective Experience at Istituto Oncologico Veneto (IOV)
- Author
-
Silvestri, G., Giarratano, T., Sommacal, S., Mioranza, E., Giorgi, C.A., Serpentini, S., Ronconi, L., Bottosso, M., Barbieri, C., Guarneri, V., and Falci, C.
- Published
- 2022
- Full Text
- View/download PDF
22. Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts
- Author
-
Frezzini, S., Giarratano, T., Griguolo, G., Piccin, L., Mioranza, E., Giorgi, C. A., Menichetti, A., Miglietta, F., Genovesi, E., Cumerlato, E., Bottosso, M., Angelini, S., Vernaci, G., Dieci, M. V., and V. Guarneri.
- Published
- 2019
23. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study
- Author
-
Dieci, M. V., Guarneri, V., Zustovich, F., Mion, M., Morandi, P., Bria, Emilio, Merlini, L., Bullian, P., Oliani, C., Gori, S., Giarratano, T., Orvieto, E., Griguolo, G., Michieletto, S., Saibene, T., Del Bianco, P., De Salvo, G. L., Conte, Pietro, Bria E. (ORCID:0000-0002-2333-704X), Dieci, M. V., Guarneri, V., Zustovich, F., Mion, M., Morandi, P., Bria, Emilio, Merlini, L., Bullian, P., Oliani, C., Gori, S., Giarratano, T., Orvieto, E., Griguolo, G., Michieletto, S., Saibene, T., Del Bianco, P., De Salvo, G. L., Conte, Pietro, and Bria E. (ORCID:0000-0002-2333-704X)
- Abstract
Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. Materials and Methods: Nine centers participated. Physicians used the RS test whenever unsure about adjuvant treatment recommendation for patients with estrogen receptor-positive/human epidermal growth receptor 2-negative, T1–T3, N0–N1 early breast cancer. Pre-RS and post-RS treatment recommendations were collected. Results: A total of 251 patients were included. N0 patients (61%) showed higher grade (p <.001) and higher Ki67 (p =.001) and were more frequently progesterone receptor negative (p =.012) as compared with N1 patients. RS results were as follows: <11, n = 63 (25.1%); 11–25, n = 143 (57%); and ≥26, n = 45 (17.9%). Higher RS was found in N0 vs. N1 patients (p =.001) and in cases of G3 (p <.001) and higher Ki67 (p <.001). The rate of change in treatment decision was 30% (n = 75), mostly from chemotherapy (CT) plus hormone therapy (CT + HT) to hormone therapy (HT; 76%, n = 57/75). The proportion of patients recommended to CT + HT was significantly reduced from pre-RS to post-RS (52% to 36%, p <.0001). CT use reduction was more evident for N1 patients (55% to 27%) than for N0 patients (50% to 42%) and was observed only in cases of RS ≤17. Conclusion: Physicians predominantly used the 21-gene assay in N0 patients with a more aggressive biology or in N1 patients showing more indolent biology. In this selected patient population, the use of RS testing led to a 30% rate of change in treatment decision. In the N1 patient subgroup, the use of RS testing contributed to reduce CT use by more than half. Implications for Practice: This study shows that, even in a context in which physicians recommend a high proportion of patients to endocrine treatment alone before knowing the results of the Recurrence Score (RS) assay, the use of the RS test, whenever uncertainty regarding
- Published
- 2019
24. ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
- Author
-
Griguolo, G., primary, Brasó-Maristany, F., additional, Pascual, T., additional, Chic, N., additional, Vidal, M., additional, Adamo, B., additional, Giarratano, T., additional, Dieci, M.V., additional, Guarneri, V., additional, and Prat, A., additional
- Published
- 2019
- Full Text
- View/download PDF
25. Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patients
- Author
-
Frezzini, S, primary, Giarratano, T, additional, Dieci, MV, additional, Giorgi, CA, additional, Griguolo, G, additional, Vernaci, G, additional, Menichetti, A, additional, Mantiero, M, additional, Tasca, G, additional, Faggioni, G, additional, Falci, C, additional, Miglietta, F, additional, Mioranza, E, additional, Angelini, S, additional, Ghiotto, C, additional, Conte, P, additional, and Guarneri, V, additional
- Published
- 2019
- Full Text
- View/download PDF
26. Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O, primary, D'Onofrio, L, additional, Blondeaux, E, additional, Bertolini, I, additional, Giarratano, T, additional, Beano, A, additional, Saggia, C, additional, Cazzaniga, M, additional, LaVerde, N, additional, Collovà, E, additional, Milani, A, additional, De Conciliis, E, additional, Coltelli, L, additional, Airoldi, M, additional, Del Mastro, L, additional, Cursano, MC, additional, Michelotti, A, additional, Vandone, AM, additional, Guarneri, V, additional, Donadio, M, additional, Riva, F, additional, Nuzzo, A, additional, and Merlano, MC, additional
- Published
- 2018
- Full Text
- View/download PDF
27. Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study
- Author
-
Giarratano, T., primary, Dieci, M.V., additional, Guarneri, V., additional, Grosso, D., additional, Zanocco, M., additional, Faggioni, G., additional, Falci, C., additional, Ghiotto, C., additional, Giorgi, C.A., additional, Griguolo, G., additional, Mioranza, E., additional, Pernice, G., additional, Vernaci, G., additional, and Conte, P., additional
- Published
- 2017
- Full Text
- View/download PDF
28. From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O., primary, Cursano, M.C., additional, De Angelis, C., additional, Giarratano, T., additional, Saggia, C., additional, Beano, A., additional, Cazzaniga, M., additional, La Verde, N., additional, Milani, A., additional, Collovà, E., additional, Coltelli, L., additional, de Conciliis, E., additional, Vandone, A.M., additional, Airoldi, M., additional, D'Onofrio, L., additional, Bertolini, I., additional, Guarneri, V., additional, Donadio, M., additional, Riva, F., additional, and Merlano, M.C., additional
- Published
- 2017
- Full Text
- View/download PDF
29. First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients
- Author
-
Dieci, M.V., primary, Guarneri, V., additional, Giarratano, T., additional, Mion, M., additional, Tortora, G., additional, Morandi, P., additional, Gori, S., additional, Merlini, L., additional, Oliani, C., additional, Pasini, F., additional, Bonciarelli, G., additional, Griguolo, G., additional, Orvieto, E., additional, Del Bianco, P., additional, De Salvo, G.L., additional, and Conte, P., additional
- Published
- 2017
- Full Text
- View/download PDF
30. 192P - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study
- Author
-
Dieci, M.V., Giorgi, C.A., Griguolo, G., Angelini, S., Miglietta, F., Giarratano, T., Falci, C., Faggioni, G., Tasca, G., Mioranza, E., Vernaci, G., Menichetti, A., Mantiero, M., Genovesi, E., Frezzini, S., Michieletto, S., Guarneri, V., and Saibene, T.
- Published
- 2019
- Full Text
- View/download PDF
31. Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastases
- Author
-
Griguolo, G, primary, Dieci, MV, additional, Giarratano, T, additional, Giorgi, CA, additional, Orvieto, E, additional, Ghiotto, C, additional, Falci, C, additional, Mioranza, E, additional, Tasca, G, additional, Milite, N, additional, Miglietta, F, additional, Conte, P, additional, and Guarneri, V, additional
- Published
- 2017
- Full Text
- View/download PDF
32. 178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease.
- Author
-
Miglietta, F., Nicolè, L., Iannaccone, D., Giarratano, T., Massa, D., Griguolo, G., Giorgi, C.A., Righetto, A., Girardi, F., Zurlo, C., Porra, F., Zanghi, F., Vernaci, G., Fassan, M., Guarneri, V., and Dieci, M.V.
- Subjects
- *
METASTATIC breast cancer , *PROGRAMMED death-ligand 1 , *PHENOTYPES - Published
- 2024
- Full Text
- View/download PDF
33. Higher Fluid Balance Increases the Risk of Death From Sepsis: Results From a Large International Audit
- Author
-
Sakr Y., Rubatto Birri P. N., Kotfis K., Nanchal R., Shah B., Kluge S., Schroeder M. E., Marshall J. C., Vincent J. -L, E Tomas, E Amisi Bibonge, B Charra, M Faroudy, L Doedens, Z Farina, D Adler, C Balkema, A Kok, S Alaya, H Gharsallah, D Muzha, A Temelkov, G Georgiev, G Simeonov, G Tsaryanski, S Georgiev, A Seliman, S Vrankovic, Z Vucicevic, I Gornik, B Barsic, I Husedzinovic, P Pavlik, J Manak, E Kieslichova, R Turek, M Fischer, R Valkova, L Dadak, P Dostal, J Malaska, R Hajek, A Židková, P Lavicka, J Starkopf, Z Kheladze, M Chkhaidze, V Kaloiani, L Medve, A Sarkany, I Kremer, Z Marjanek, P Tamasi, I Krupnova, I Vanags, V Liguts, V Pilvinis, S Vosylius, G Kekstas, M Balciunas, J Kolbusz, A Kübler, B Mielczarek, M Mikaszewska-Sokolewicz, K Kotfis, B Tamowicz, W Sulkowski, P Smuszkiewicz, A Pihowicz, E Trejnowska, N Hagau, D Filipescu, G Droc, M Lupu, A Nica, R Stoica, D Tomescu, D Constantinescu, G Valcoreanu Zbaganu, A Slavcovici, V Bagin, D Belsky, S Palyutin, S Shlyapnikov, D Bikkulova, A Gritsan, G Natalia, E Makarenko, V Kokhno, A Tolkach, E Kokarev, B Belotserkovskiy, K Zolotukhin, V Kulabukhov, L Soskic, I Palibrk, R Jankovic, B Jovanovic, M Pandurovic, V Bumbasirevic, B Uljarevic, M Surbatovic, N Ladjevic, G Slobodianiuk, V Sobona, A Cikova, A Gebhardtova, C Jun, S Yunbo, J Dong, S Feng, M Duan, Y Xu, X Xue, T Gao, X Xing, X Zhao, C Li, G Gengxihua, H Tan, J Xu, L Jiang, Q Tiehe, Q Bingyu, Q Shi, Z Lv, L Zhang, L Jingtao, Z Zhen, Z Wang, T Wang, L Yuhong, Q Zhai, Y Chen, C Wang, W Jiang, W Ruilan, Y Chenv, H Xiaobo, H Ge, T Yan, C Yuhui, J Zhang, F Jian-Hong, H Zhu, F Huo, Y Wang, M Zhuang, Z Ma, J Sun, L Liuqingyue, M Yang, J Meng, S Ma, Y Kang, L Yu, Q Peng, Y Wei, W Zhang, R Sun, A Yeung, W Wan, K Sin, K Lee, M Wijanti, U Widodo, H Samsirun, T Sugiman, C Wisudarti, T Maskoen, N Hata, Y Kobe, O Nishida, D Miyazaki, S Nunomiya, S Uchino, N Kitamura, K Yamashita, S Hashimoto, H Fukushima, N Nik Adib, L Tai, B Tony, R Bigornia, J Palo, S Chatterjee, B Tan, A Kong, S Goh, C Lee, C Pothirat, B Khwannimit, P Theerawit, P Pornsuriyasak, A Piriyapatsom, A Mukhtar, A Nabil Hamdy, H Hosny, A Ashraf, M Mokhtari, S Nowruzinia, A Lotfi, F Zand, R Nikandish, O Moradi Moghaddam, J Cohen, O Sold, T Sfeir, A Hasan, D Abugaber, H Ahmad, T Tantawy, S Baharoom, H Algethamy, A Amr, G Almekhlafi, R Coskun, M Sungur, A Cosar, B Güçyetmez, O Demirkiran, E Senturk, H Ulusoy, H Atalan, S Serin, I Kati, Z Alnassrawi, A Almemari, K Krishnareddy, S Kashef, A Alsabbah, G Poirier, J Marshall, M Herridge, R Fernandez-Medero, G Fulda, S Banschbach, J Quintero, E Schroeder, C Sicoutris, R Gueret, R Kashyap, P Bauer, R Nanchal, R Wunderink, E Jimenez, A Ryan, D Prince, J Edington, F Van Haren, A Bersten, D J Hawkins, M Kilminster, D Sturgess, M Ziegenfuss, S O' Connor, J Lipman, L Campbell, R Mcallister, B Roberts, P Williams, R Parke, P Seigne, R Freebairn, D Nistor, C Oxley, P Young, R Valentini, N Wainsztein, P Comignani, M Casaretto, G Sutton, P Villegas, C Galletti, J Neira, D Rovira, J Hidalgo, F Sandi, E Caser, M Thompson, M D'agostino Dias, L Fontes, M Lunardi, N Youssef, S Lobo, R Silva, J Sales Jr, L Madeira Campos Melo, M Oliveira, M Fonte, C Grion, C Feijo, V Rezende, M Assuncao, A Neves, P Gusman, D Dalcomune, C Teixeira, K Kaefer, I Maia, V Souza Dantas, R Costa Filho, F Amorim, M Assef, P Schiavetto, J Houly, F Bianchi, F Dias, C Avila, J Gomez, L Rego, P Castro, J Passos, C Mendes, G Colozza Mecatti, M Ferrreira, V Irineu, M Guerreiro, S Ugarte, V Tomicic, C Godoy, W Samaniego, I Escamilla, L Castro Castro, G Libreros Duque, D Diaz-Guio, F Benítez, A Guerra Urrego, R Buitrago, G Ortiz, M Villalba Gaviria, D Salas, J Ramirez-Arce, E Salgado, D Morocho, J Vergara, M Chung Sang, C Orellana-Jimenez, L Garrido, O Diaz, D Resiere, C Osorio, A De La Vega, R Carrillo, V Sanchez, A Villagomez, R Martinez Zubieta, M Sandia, M Zalatiel, M Poblano, D Rodriguez Gonzalez, F Arrazola, L Juan Francisco, S A Ñamendys-Silva, M Hernandez, D Rodriguez Cadena, I Lopez Islas, C Ballesteros Zarzavilla, A Matos, I Oyanguren, J Cerna, R Quispe Sierra, R Jimenez, L Castillo, R Ocal, A Sencan, S Mareque Gianoni, A Deicas, J Hurtado, G Burghi, A Martinelli, I Von Der Osten, C Du Maine, M Bhattacharyya, S Bandyopadhyay, S Yanamala, P Gopal, S Sahu, M Ibrahim, D Rathod, N Mukundan, A Dewan, P Amin, S Samavedam, B Shah, D Gurupal, B Lahkar, A Mandal, M Sircar, S Ghosh, V Balasubramani, F Kapadia, S Vadi, K Nair, S Tripathy, S Nandakumar, J Sharma, A Kar, S Jha, K Zirpe-Gurav, M Patel, A Bhavsar, D Samaddar, A Kulkarni, M Hashmi, W Ali, S Nadeem, K Indraratna, A Margarit, P Urbanek, J Schlieber, J Reisinger, J Auer, A Hartjes, A Lerche, T Janous, E Kink, W Krahulec, K Smolle, M Van Der Schueren, P Thibo, M Vanhoof, I Ahmet, G Philippe, P Dufaye, O Jacobs, V Fraipont, P Biston, A Dive, Y Bouckaert, E Gilbert, B Gressens, E Pinck, V Collin, J L Vincent, J De Waele, R Rimachi, D Gusu, K De Decker, K Mandianga, L Heytens, X Wittebole, S Herbert, V Olivier, W Vandenheede, P Rogiers, P Kolodzeike, M Kruse, T Andersen, V Harjola, K Saarinen, M Leone, A Durocher, S Moulront, A Lepape, M Losser, P Cabaret, E Kalaitzis, E Zogheib, P Charve, B Francois, J Y Lefrant, B Beilouny, X Forceville, B Misset, F Jacobs, F Bernard, D Payen, A Wynckel, V Castelain, A Faure, P Lavagne, L Thierry, M Moussa, A Vieillard-Baron, M Durand, M Gainnier, C Ichai, S Arens, C Hoffmann, M Kaffarnik, C Scharnofske, I Voigt, C Peckelsen, M Weber, J Gille, A Lange, G Schoser, A Sablotzki, U Jaschinski, A Bluethgen, F Vogel, A Tscheu, T Fuchs, M Wattenberg, T Helmes, S Scieszka, M Heintz, S Sakka, J Kohler, F Fiedler, M Danz, Y Sakr, R Riessen, T Kerz, A Kersten, F Tacke, G Marx, T Volkert, A Schmutz, A Nierhaus, S Kluge, P Abel, R Janosi, S Utzolino, H Bracht, S Toussaint, M Giannakou Peftoulidou, P Myrianthefs, A Armaganidis, C Routsi, A Xini, E Mouloudi, I Kokoris, G Kyriazopoulos, S Vlachos, A Lavrentieva, P Partala, G Nakos, A Moller, S Stefansson, J Barry, R O'Leary, C Motherway, M Faheem, E Dunne, M Donnelly, T Konrad, E Bonora, C Achilli, S Rossi, G Castiglione, A Peris, D Albanese, N Stocchetti, G Citerio, L Mozzoni, E Sisillo, P De Negri, M Savioli, P Vecchiarelli, F Puflea, V Stankovic, G Minoja, S Montibeller, P Calligaro, R Sorrentino, M Feri, M Zambon, E Colombaroli, A Giarratano, T Pellis, C Capra, M Antonelli, A Gullo, C Chelazzi, A De Capraris, N Patroniti, M Girardis, F Franchi, G Berlot, M Buttigieg, H Ponssen, J Ten Cate, L Bormans, S Husada, M Buise, B Van Der Hoven, A Reidinga, M Kuiper, P Pickkers, G Kluge, S Den Boer, J Kesecioglu, H Van Leeuwen, H Flaatten, S Mo, V Branco, F Rua, E Lafuente, M Sousa, N Catorze, M Barros, L Pereira, A Vintém De Oliveira, J Gomes, I Gaspar, M Pereira, M Cymbron, A Dias, E Almeida, S Beirao, I Serra, R Ribeiro, P Povoa, F Faria, Z Costa-E-Silva, J Nóbrega, F Fernandes, J Gabriel, G Voga, E Rupnik, L Kosec, M Kerin Povšic, I Osojnik, V Tomic, A Sinkovic, J González, E Zavala, J Pérez Valenzuela, L Marina, P Vidal-Cortés, P Posada, A Ignacio Martin-Loeches, N Muñoz Guillén, M Palomar, J Sole-Violan, A Torres, M Gonzalez Gallego, G Aguilar, R Montoiro Alluév, M Argüeso, M Parejo, M Palomo Navarro, A Jose, N Nin, F Alvarez Lerma, O Martinez, E Tenza Lozano, S Arenal López, M Perez Granda, S Moreno, C Llubia, C De La Fuente Martos, P Gonzalez-Arenas, N Llamas Fernández, B Gil Rueda, I Estruch Pons, N Cruza, F Maroto, A Estella, A Ferrer, L Iglesias Fraile, B Quindos, A Quintano, M Tebar, P Cardinal, A Reyes, A Rodríguez, A Abella, S García Del Valle, S Yus, E Maseda, J Berezo, A Tejero Pedregosa, C Laplaza, R Ferrer, J Rico-Feijoo, M Rodríguez, P Monedero, K Eriksson, D Lind, D Chabanel, H Zender, K Heer, B Frankenberger, S Jakob, A Haller, S Mathew, R Downes, C Barrera Groba, A Johnston, R Meacher, R Keays, P Haji-Michael, C Tyler, A Ferguson, S Jones, D Tyl, A Ball, J Vogel, M Booth, P Downie, M Watters, S Brett, M Garfield, L Everett, S Heenen, S Dhir, Z Beardow, M Mostert, S Brosnan, N Pinto, S Harris, A Summors, N Andrew, A Rose, R Appelboam, O Davies, E Vickers, B Agarwal, T Szakmany, S Wimbush, I Welters, R Pearse, R Hollands, J Kirk-Bayley, N Fletcher, B Bray, D Brealey, Sakr, Y, Rubatto Birri, P, Kotfis, K, Nanchal, R, Shah, B, Kluge, S, Schroeder, M, Marshall, J, Vincent, J, Citerio, G, Sakr Y., Rubatto Birri P.N., Kotfis K., Nanchal R., Shah B., Kluge S., Schroeder M.E., Marshall J.C., and Vincent J.-L, E Tomas, E Amisi Bibonge, B Charra, M Faroudy, L Doedens, Z Farina, D Adler, C Balkema, A Kok, S Alaya, H Gharsallah, D Muzha, A Temelkov, G Georgiev, G Simeonov, G Tsaryanski, S Georgiev, A Seliman, S Vrankovic, Z Vucicevic, I Gornik, B Barsic, I Husedzinovic, P Pavlik, J Manak, E Kieslichova, R Turek, M Fischer, R Valkova, L Dadak, P Dostal, J Malaska, R Hajek, A Židková, P Lavicka, J Starkopf, Z Kheladze, M Chkhaidze, V Kaloiani, L Medve, A Sarkany, I Kremer, Z Marjanek, P Tamasi, I Krupnova, I Vanags, V Liguts, V Pilvinis, S Vosylius, G Kekstas, M Balciunas, J Kolbusz, A Kübler, B Mielczarek, M Mikaszewska-Sokolewicz, K Kotfis, B Tamowicz, W Sulkowski, P Smuszkiewicz, A Pihowicz, E Trejnowska, N Hagau, D Filipescu, G Droc, M Lupu, A Nica, R Stoica, D Tomescu, D Constantinescu, G Valcoreanu Zbaganu, A Slavcovici, V Bagin, D Belsky, S Palyutin, S Shlyapnikov, D Bikkulova, A Gritsan, G Natalia, E Makarenko, V Kokhno, A Tolkach, E Kokarev, B Belotserkovskiy, K Zolotukhin, V Kulabukhov, L Soskic, I Palibrk, R Jankovic, B Jovanovic, M Pandurovic, V Bumbasirevic, B Uljarevic, M Surbatovic, N Ladjevic, G Slobodianiuk, V Sobona, A Cikova, A Gebhardtova, C Jun, S Yunbo, J Dong, S Feng, M Duan, Y Xu, X Xue, T Gao, X Xing, X Zhao, C Li, G Gengxihua, H Tan, J Xu, L Jiang, Q Tiehe, Q Bingyu, Q Shi, Z Lv, L Zhang, L Jingtao, Z Zhen, Z Wang, T Wang, L Yuhong, Q Zhai, Y Chen, C Wang, W Jiang, W Ruilan, Y Chenv, H Xiaobo, H Ge, T Yan, C Yuhui, J Zhang, F Jian-Hong, H Zhu, F Huo, Y Wang, C Li, M Zhuang, Z Ma, J Sun, L Liuqingyue, M Yang, J Meng, S Ma, Y Kang, L Yu, Q Peng, Y Wei, W Zhang, R Sun, A Yeung, W Wan, K Sin, K Lee, M Wijanti, U Widodo, H Samsirun, T Sugiman, C Wisudarti, T Maskoen, N Hata, Y Kobe, O Nishida, D Miyazaki, S Nunomiya, S Uchino, N Kitamura, K Yamashita, S Hashimoto, H Fukushima, N Nik Adib, L Tai, B Tony, R Bigornia, R Bigornia, R Bigornia, J Palo, S Chatterjee, B Tan, A Kong, S Goh, C Lee, C Pothirat, B Khwannimit, P Theerawit, P Pornsuriyasak, A Piriyapatsom, A Mukhtar, A Nabil Hamdy, H Hosny, A Ashraf, M Mokhtari, S Nowruzinia, A Lotfi, F Zand, R Nikandish, O Moradi Moghaddam, J Cohen, O Sold, T Sfeir, A Hasan, D Abugaber, H Ahmad, T Tantawy, S Baharoom, H Algethamy, A Amr, G Almekhlafi, R Coskun, M Sungur, A Cosar, B Güçyetmez, O Demirkiran, E Senturk, H Ulusoy, H Atalan, S Serin, I Kati, Z Alnassrawi, A Almemari, K Krishnareddy, S Kashef, A Alsabbah, G Poirier, J Marshall, M Herridge, M Herridge, R Fernandez-Medero, G Fulda, S Banschbach, J Quintero, E Schroeder, C Sicoutris, R Gueret, R Kashyap, P Bauer, R Nanchal, R Wunderink, E Jimenez, A Ryan, D Prince, J Edington, F Van Haren, A Bersten, D J Hawkins, M Kilminster, D Sturgess, M Ziegenfuss, S O' Connor, J Lipman, L Campbell, R Mcallister, B Roberts, P Williams, R Parke, P Seigne, R Freebairn, D Nistor, C Oxley, P Young, R Valentini, N Wainsztein, P Comignani, M Casaretto, G Sutton, P Villegas, C Galletti, J Neira, D Rovira, J Hidalgo, F Sandi, E Caser, M Thompson, M D'agostino Dias, L Fontes, M Lunardi, N Youssef, S Lobo, R Silva, J Sales Jr, L Madeira Campos Melo, M Oliveira, M Fonte, C Grion, C Feijo, V Rezende, M Assuncao, A Neves, P Gusman, D Dalcomune, C Teixeira, K Kaefer, I Maia, V Souza Dantas, R Costa Filho, F Amorim, M Assef, P Schiavetto, J Houly, F Bianchi, F Dias, C Avila, J Gomez, L Rego, P Castro, J Passos, C Mendes, C Grion, G Colozza Mecatti, M Ferrreira, V Irineu, M Guerreiro, S Ugarte, V Tomicic, C Godoy, W Samaniego, I Escamilla, L Castro Castro, G Libreros Duque, D Diaz-Guio, F Benítez, A Guerra Urrego, R Buitrago, G Ortiz, M Villalba Gaviria, D Salas, J Ramirez-Arce, E Salgado, D Morocho, J Vergara, M Chung Sang, C Orellana-Jimenez, L Garrido, O Diaz, D Resiere, C Osorio, A De La Vega, R Carrillo, V Sanchez, A Villagomez, R Martinez Zubieta, M Sandia, M Zalatiel, M Poblano, D Rodriguez Gonzalez, F Arrazola, L Juan Francisco, S A Ñamendys-Silva, M Hernandez, D Rodriguez Cadena, I Lopez Islas, C Ballesteros Zarzavilla, A Matos, I Oyanguren, J Cerna, R Quispe Sierra, R Jimenez, L Castillo, R Ocal, A Sencan, S Mareque Gianoni, A Deicas, J Hurtado, G Burghi, A Martinelli, I Von Der Osten, C Du Maine, M Bhattacharyya, S Bandyopadhyay, S Yanamala, P Gopal, S Sahu, M Ibrahim, D Rathod, N Mukundan, A Dewan, P Amin, S Samavedam, B Shah, D Gurupal, B Lahkar, A Mandal, M Sircar, S Ghosh, V Balasubramani, F Kapadia, S Vadi, K Nair, S Tripathy, S Nandakumar, J Sharma, A Kar, S Jha, K Zirpe-Gurav, M Patel, A Bhavsar, D Samaddar, A Kulkarni, M Hashmi, W Ali, S Nadeem, K Indraratna, A Margarit, P Urbanek, J Schlieber, J Reisinger, J Auer, A Hartjes, A Lerche, T Janous, E Kink, W Krahulec, K Smolle, M Van Der Schueren, P Thibo, M Vanhoof, I Ahmet, G Philippe, P Dufaye, O Jacobs, V Fraipont, P Biston, A Dive, Y Bouckaert, E Gilbert, B Gressens, E Pinck, V Collin, J L Vincent, J De Waele, R Rimachi, D Gusu, K De Decker, K Mandianga, L Heytens, X Wittebole, S Herbert, V Olivier, W Vandenheede, P Rogiers, P Kolodzeike, M Kruse, T Andersen, V Harjola, K Saarinen, M Leone, A Durocher, S Moulront, A Lepape, M Losser, P Cabaret, E Kalaitzis, E Zogheib, P Charve, B Francois, J Y Lefrant, B Beilouny, X Forceville, B Misset, F Jacobs, F Bernard, D Payen, A Wynckel, V Castelain, A Faure, P Lavagne, L Thierry, M Moussa, A Vieillard-Baron, M Durand, M Gainnier, C Ichai, S Arens, C Hoffmann, M Kaffarnik, C Scharnofske, I Voigt, C Peckelsen, M Weber, J Gille, A Lange, G Schoser, A Sablotzki, U Jaschinski, A Bluethgen, F Vogel, A Tscheu, T Fuchs, M Wattenberg, T Helmes, S Scieszka, M Heintz, S Sakka, J Kohler, F Fiedler, M Danz, Y Sakr, R Riessen, T Kerz, A Kersten, F Tacke, G Marx, T Volkert, A Schmutz, A Nierhaus, S Kluge, P Abel, R Janosi, S Utzolino, H Bracht, S Toussaint, M Giannakou Peftoulidou, P Myrianthefs, A Armaganidis, C Routsi, A Xini, E Mouloudi, I Kokoris, G Kyriazopoulos, S Vlachos, A Lavrentieva, P Partala, G Nakos, A Moller, S Stefansson, J Barry, R O'Leary, C Motherway, M Faheem, E Dunne, M Donnelly, T Konrad, E Bonora, C Achilli, S Rossi, G Castiglione, A Peris, D Albanese, N Stocchetti, G Citerio, L Mozzoni, E Sisillo, P De Negri, M Savioli, P Vecchiarelli, F Puflea, V Stankovic, G Minoja, S Montibeller, P Calligaro, R Sorrentino, M Feri, M Zambon, E Colombaroli, A Giarratano, T Pellis, C Capra, M Antonelli, A Gullo, C Chelazzi, A De Capraris, N Patroniti, M Girardis, F Franchi, G Berlot, M Buttigieg, H Ponssen, J Ten Cate, L Bormans, S Husada, M Buise, B Van Der Hoven, A Reidinga, M Kuiper, P Pickkers, G Kluge, S Den Boer, J Kesecioglu, H Van Leeuwen, H Flaatten, S Mo, V Branco, F Rua, E Lafuente, M Sousa, N Catorze, M Barros, L Pereira, A Vintém De Oliveira, J Gomes, I Gaspar, M Pereira, M Cymbron, A Dias, E Almeida, S Beirao, I Serra, R Ribeiro, P Povoa, F Faria, Z Costa-E-Silva, J Nóbrega, F Fernandes, J Gabriel, G Voga, E Rupnik, L Kosec, M Kerin Povšic, I Osojnik, V Tomic, A Sinkovic, J González, E Zavala, J Pérez Valenzuela, L Marina, P Vidal-Cortés, P Posada, A Ignacio Martin-Loeches, N Muñoz Guillén, M Palomar, J Sole-Violan, A Torres, M Gonzalez Gallego, G Aguilar, R Montoiro Alluév, M Argüeso, M Parejo, M Palomo Navarro, A Jose, N Nin, F Alvarez Lerma, O Martinez, E Tenza Lozano, S Arenal López, M Perez Granda, S Moreno, C Llubia, C De La Fuente Martos, P Gonzalez-Arenas, N Llamas Fernández, B Gil Rueda, I Estruch Pons, N Cruza, F Maroto, A Estella, A Ferrer, L Iglesias Fraile, B Quindos, A Quintano, M Tebar, P Cardinal, A Reyes, A Rodríguez, A Abella, S García Del Valle, S Yus, E Maseda, J Berezo, A Tejero Pedregosa, C Laplaza, R Ferrer, J Rico-Feijoo, M Rodríguez, P Monedero, K Eriksson, D Lind, D Chabanel, H Zender, K Heer, B Frankenberger, S Jakob, A Haller, S Mathew, R Downes, C Barrera Groba, A Johnston, R Meacher, R Keays, P Haji-Michael, C Tyler, A Ferguson, S Jones, D Tyl, A Ball, J Vogel, M Booth, P Downie, M Watters, S Brett, M Garfield, L Everett, S Heenen, S Dhir, Z Beardow, M Mostert, S Brosnan, N Pinto, S Harris, A Summors, N Andrew, A Rose, R Appelboam, O Davies, E Vickers, B Agarwal, T Szakmany, S Wimbush, I Welters, R Pearse, R Hollands, J Kirk-Bayley, N Fletcher, B Bray, D Brealey
- Subjects
Internationality ,Time Factors ,Databases, Factual ,medicine.medical_treatment ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Settore MED/41 - Anestesiologia ,Critical Care and Intensive Care Medicine ,law.invention ,0302 clinical medicine ,law ,Risk Factors ,80 and over ,030212 general & internal medicine ,Hospital Mortality ,610 Medicine & health ,Aged, 80 and over ,Medical Audit ,fluid output ,Middle Aged ,Water-Electrolyte Balance ,fluid administration ,Intensive care unit ,outcome ,septic shock ,Adult ,Aged ,Humans ,Intensive Care Units ,Sepsis ,Fluid Therapy ,Cohort ,Human ,Cohort study ,medicine.medical_specialty ,Time Factor ,Sepsi ,Intensive Care Unit ,Observational Study ,03 medical and health sciences ,Databases ,Hemofiltration ,medicine ,Journal Article ,Risk factor ,Intensive care medicine ,Factual ,Hetastarch ,business.industry ,Septic shock ,Risk Factor ,030208 emergency & critical care medicine ,fluid administration, fluid output, outcome, septic shock ,medicine.disease ,business - Abstract
Contains fulltext : 177598.pdf (Publisher’s version ) (Closed access) OBJECTIVES: Excessive fluid therapy in patients with sepsis may be associated with risks that outweigh any benefit. We investigated the possible influence of early fluid balance on outcome in a large international database of ICU patients with sepsis. DESIGN: Observational cohort study. SETTING: Seven hundred and thirty ICUs in 84 countries. PATIENTS: All adult patients admitted between May 8 and May 18, 2012, except admissions for routine postoperative surveillance. For this analysis, we included only the 1,808 patients with an admission diagnosis of sepsis. Patients were stratified according to quartiles of cumulative fluid balance 24 hours and 3 days after ICU admission. MEASUREMENTS AND MAIN RESULTS: ICU and hospital mortality rates were 27.6% and 37.3%, respectively. The cumulative fluid balance increased from 1,217 mL (-90 to 2,783 mL) in the first 24 hours after ICU admission to 1,794 mL (-951 to 5,108 mL) on day 3 and decreased thereafter. The cumulative fluid intake was similar in survivors and nonsurvivors, but fluid balance was less positive in survivors because of higher fluid output in these patients. Fluid balances became negative after the third ICU day in survivors but remained positive in nonsurvivors. After adjustment for possible confounders in multivariable analysis, the 24-hour cumulative fluid balance was not associated with an increased hazard of 28-day in-hospital death. However, there was a stepwise increase in the hazard of death with higher quartiles of 3-day cumulative fluid balance in the whole population and after stratification according to the presence of septic shock. CONCLUSIONS: In this large cohort of patients with sepsis, higher cumulative fluid balance at day 3 but not in the first 24 hours after ICU admission was independently associated with an increase in the hazard of death.
- Published
- 2017
34. 20P ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC).
- Author
-
Griguolo, G, Brasó-Maristany, F, Pascual, T, Chic, N, Vidal, M, Adamo, B, Giarratano, T, Dieci, M V, Guarneri, V, and Prat, A
- Subjects
- *
ANTIBODY-drug conjugates , *BREAST cancer , *MESSENGER RNA , *METASTATIC breast cancer - Published
- 2019
- Full Text
- View/download PDF
35. Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.
- Author
-
Bottosso M, Miglietta F, Vernaci GM, Giarratano T, Dieci MV, Guarneri V, and Griguolo G
- Subjects
- Humans, Female, Chemotherapy, Adjuvant methods, Gene Expression Profiling, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Gene Expression Regulation, Neoplastic drug effects, Precision Medicine methods, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Breast Neoplasms metabolism, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Agents, Hormonal pharmacology, Biomarkers, Tumor genetics
- Abstract
Adjuvant endocrine therapy (ET) represents the standard of care for almost all hormone receptor (HR)+/HER2- breast cancers, and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant ET beyond currently used clinicopathological characteristics. Several gene expression assays have been developed to identify patients with HR+/HER2- breast cancer who will not derive benefit from the addition of adjuvant chemotherapy. By enhancing risk stratification and predicting therapeutic response, genomic assays have also shown to be a promising tool for optimizing endocrine treatment decisions. In this study, we review evidence supporting the use of most common commercially available gene expression assays [Oncotype DX, MammaPrint, Breast Cancer Index (BCI), Prosigna, and EndoPredict] in tailoring adjuvant ET. Available data on the use of genomic tests to inform extended adjuvant treatment choice based on the risk of late relapse and on the estimated benefit of a prolonged ET are discussed. Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low-risk patients is reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2- breast cancers., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
36. The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy.
- Author
-
Girardi F, Marini S, Porra F, Carpentieri S, Marchet A, Saibene T, Lo Mele M, Giarratano T, Giorgi CA, Mioranza E, Falci C, Faggioni G, Caumo F, Griguolo G, Dieci MV, and Guarneri V
- Subjects
- Humans, Female, Cross-Sectional Studies, Pandemics, Italy epidemiology, Breast Neoplasms drug therapy, Breast Neoplasms epidemiology, COVID-19 epidemiology
- Abstract
Introduction: The Coronavirus Disease 2019 (COVID-19) has disrupted health services worldwide. The evidence on the impact of the pandemic on cancer care provision, however, is conflicting. We aimed to audit the management of patients diagnosed with early breast cancer (EBC) during the pandemic in a large, tertiary-level cancer center in Italy., Methods: We conducted a cross-sectional study to track the route to first treatment for patients diagnosed with EBC during 2019, 2020, and 2021. We abstracted data for all consecutive patients referred to the Veneto Institute of Oncology (Padua, Italy). We defined as point of contact (POC) the date of the first consultation with a breast cancer specialist of the breast unit. First treatment was defined as either upfront surgery or neoadjuvant chemotherapy (NACT)., Results: We reviewed medical records for 878 patients for whom an MDT report during 2019-2021 (April through June) was available. Of these, 431 (49%) were eligible. The proportion of screen-detected tumors was larger in 2019 and 2021 than in 2020 (59%). Conversely, the proportion of screen-detected tumors was offset by the proportion of palpable tumors in 2020 (P = .004). Distribution of tumor and nodal stage was unchanged over time, but in situ tumors were slightly fewer in 2020 than in 2019 or 2021. The adjusted odds ratio for treatment delay (45 days or more) was 0.87 for 2020 versus 2019 (95% CI, 0.5-1.53) and 0.9 for 2021 versus 2019 (95% CI, 0.52-1.55)., Conclusions: There was no evidence for major changes in the management of patients with EBC during 2019-2021 and no treatment delays were observed. Our findings suggest that more women presented with palpable nodules at diagnosis, but the stage distribution did not change over time. Validation on a larger cohort of patients is warranted to robustly assess the impact of the COVID-19 pandemic on treatment practices for patients with EBC., (© The Author(s) 2023. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
37. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
- Author
-
Miglietta F, Dieci MV, Giarratano T, Torri V, Giuliano M, Zustovich F, Mion M, Tondini CA, De Rossi C, Bria E, Franchi M, Merlini L, Giannatiempo R, Russo D, Fotia V, Poletti P, Caremoli ER, Arpino MG, De Salvo GL, Zambelli A, and Guarneri V
- Subjects
- Humans, Female, Lymphocytes, Tumor-Infiltrating, Prospective Studies, Receptor, ErbB-2, Prognosis, Biomarkers, Tumor, Tumor Microenvironment, Breast Neoplasms drug therapy
- Abstract
Background: The clinical value of tumor infiltrating lymphocytes (TILs) in hormone receptor-positive (HR+)/HER2- breast cancer (BC) may be unearthed by focusing on more biologically aggressive tumors. Here we deepen and describe the correlation between RS and TILs, proposing an immuno-genomic model for HR+ /HER2- BC., Methods: We enrolled T1-T3, N0-N1 BC patients with available RS® and TILs in the context of four multicenter, prospective studies. RS® and TILs were considered as continuous and categorical variables. RS® was categorized into: 0-10 (low risk), 11-25 (intermediate risk) and 26-100 (high risk); TILs were categorized into: low TILs (0-10%), intermediate TILs (11-59%) and high TILs (60-100%)., Results: 811 patients were included. RS distribution was (n = 810): low risk 22.0%, intermediate risk 61.2%, high risk 16.8%. TIL distribution was (n = 455): low TILs 84.6%, intermediate TILs 13.6% and high TILs 1.8%. A significant, weak positive, linear correlation was found between continuous TILs and RS (Pearson coefficient=0.223, p < 0.001). When considering RS and TILs categories, tumors with intermediate/high TIL levels significantly enriched the high RS subgroup (p = 0.006). This was confirmed both within Luminal A and Luminal B cohorts. Among high-RS patients, 16.7% of Luminal A and 26.7% of Luminal B tumors had intermediate/high TILs., Conclusions: We observed that RS® and TILs capture only slightly overlapping information on the biology of HR+ /HER2- tumor microenvironment. We demonstrated the feasibility of combining RS and TILs into a composite immuno-genomic model, which may serve the purpose of guiding and focalizing patient selection in the further development of immunotherapy strategies for Luminal-like disease., Competing Interests: Declaration of Competing Interest FM: reports personal fees from Roche, Novartis, Gilead, Seagen, Pfizer, outside the submitted work. MVD: reports personal fees from EliLilly, Exact Sciences, Novartis, Pfizer, Seagen, Gilead, MSD, AstraZeneca, Daiichi Sankyo, and Roche outside of the submitted work. TG: reports personal fees from Gilead, Roche, outside the submitted work. MG: Consulting/Advisor: Roche, AstraZeneca, Lilly, Daichii Sankyo, Novartis, Pfizer, Seagen, MSD, Eisai; Honoraria: Novartis, Pfizer, Lilly, AstraZeneca, Daichii Sankyo; Research funding to the Institution: AstraZeneca; Travel, accommodation, expenses: Lilly, Pfizer, AstraZeneca. MM: personal fees from Accord, Gentili, Novartis, Lilly. EB: received speakers’ and travels’ fee from MSD, Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis and Roche. AZ: reports personal fees and non-financial support from Novartis, Astra-Zeneca, Eli-Lilly, Pfizer, Daiichi Sankyo, MSD, Roche, Seagen, Exact Sciences, Gilead, all disclosures are outside the submitted work. VG: reports personal fees for advisory board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre; personal fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Novartis, Roche and Zentiva; personal fees for expert testimony for Eli Lilly. All remaining authors have declared no conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
38. Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
- Author
-
Vernaci G, Savarino EV, Patuzzi I, Facchin S, Zingone F, Massa D, Faggioni G, Giarratano T, Miglietta F, Griguolo G, Fassan M, Lo Mele M, Gasparini E, Bisagni G, Guarneri V, and Dieci MV
- Subjects
- Humans, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Anthracyclines adverse effects, Triple Negative Breast Neoplasms pathology, Gastrointestinal Microbiome
- Abstract
Introduction: Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored., Methods: Microbiome was analyzed by 16SrRNA sequencing., Results: Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time., Conclusions: Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer., (© The Author(s) 2023. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
39. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
- Author
-
Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, Giarratano T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, Vernieri C, and Curigliano G
- Subjects
- Female, Humans, BRCA1 Protein genetics, BRCA2 Protein genetics, Germ Cells pathology, Platinum therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors, Retrospective Studies, Middle Aged, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics
- Abstract
Introduction: Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi). As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap. In patients with a gBRCA-PV and advanced BC (aBC), it remains unclear whether prior exposure to PARPi/PBC affects tumour response to subsequent PBC/PARPi, respectively., Methods: We conducted a retrospective, multicentric study to investigate the clinical benefit of post-PBC PARPi and vice versa in patients with a gBRCA-PV and aBC. Patients included had received (neo)adjuvant PBC and then PARPi in advanced setting (group 1), PBC followed by PARPi (group 2) or PARPi followed by PBC (group 3), both in advanced setting. We reported median progression-free survival (mPFS) and disease control rate (DCR) in each group., Results: A total of 67 patients from six centres were included. PARPi-mPFS in advanced setting was 6.1 months in patients in group 1 (N = 12), while PARPi-DCR was 67%. In group 2 (N = 36), PARPi-mPFS was 3.4 months and PARPi-DCR was 64%. Age < 65 years and platinum-free interval (PFI) > 6 months were associated with longer PARPi-PFS; previous PBC-PFS > 6 months and PBC in first to second line were associated with longer PARPi-DCR. Patients in group 3 (N = 21) reported a PBC-mPFS of 1.8 months and a PBC-DCR of 14%. PARPi-PFS ≥ 9 months and PARPi-FI ≥ 6 months were associated with better PBC-DCR., Conclusions: Sensitivity and resistance to PARPi and PBC partially overlap in patients with a gBRCA-PV and aBC. Evidence of PARPi activity emerged in patients who progressed on previous PBC., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GC reports honoraria for speaker's engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, MSD; honoraria for providing consultancy: Roche, Seattle Genetics, NanoString; Honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; honoraria for writing engagement: Novartis, BMS; Honoraria for participation in Ellipsis Scientific Affairs Group; institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune. LM reports honoraria for speakers engagement: Roche, Pfizer, Eli Lilly, Gilead, Daichii Sankyo, Novartis. Honoraria for participating in Advisory Board: EISAI, Pfizer, Roche. ML reports advisory role for Roche, Lilly, Novartis, Astrazeneca, Pfizer, Seagen, Gilead, MSD and Exact Sciences; speaker honoraria from Roche, Lilly, Novartis, Pfizer, Sandoz, Libbs, Daiichi Sankyo and Takeda; Travel Grants from Gilead; research support (to the Institution) from Gilead, all outside the submitted work. AZ reports advisory role for Roche, Lilly, Novartis, Astrazeneca, Pfizer, Seagen, Gilead, MSD and Exact Sciences; speaker honoraria from Roche, Lilly, Novartis, Daiichi Sankyo; Travel Grants from Gilead, Daiichi Sankyo; all outside the submitted work. MP reports advisory role for Lilly, Novartis, Astrazeneca, Pfizer, Gilead; speaker honoraria from Lilly, Novartis, Pfizer, Daiichi Sankyo; Travel Grants from Gilead; all outside the submitted work. CVe reports honoraria for speaker's engagement: Lilly, Pfizer, Novartis, Istituto Gentili, Accademia di Medicina, Fenix; honoraria for participating in advisory boards: Pfizer, Novartis, lilly, Daichi Sankyo; research grants: Roche. All the competing interests were outside the submitted work. All other authors have no potential conflict of interest to disclose., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
- Author
-
Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, Vidal M, Adamo B, Muñoz M, Sanfeliu E, González B, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A, and Guarneri V
- Subjects
- Humans, Female, Ado-Trastuzumab Emtansine therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Trastuzumab therapeutic use, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, RNA, Messenger genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism, Maytansine therapeutic use
- Abstract
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P < .001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P = .002) and overall survival (OS; P = .02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P = .04) and immunoglobulin signature (P = .04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
41. Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
- Author
-
Fontanella C, Giorgi CA, Russo S, Angelini S, Nicolardi L, Giarratano T, Frezzini S, Pestrin M, Palleschi D, Bolzonello S, Parolin V, Haspinger ER, De Rossi C, Greco F, and Gerratana L
- Subjects
- Female, Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Quality of Life, Receptor, ErbB-2 metabolism, Breast Neoplasms metabolism, Protein Kinase Inhibitors pharmacology
- Abstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are now a backbone of treatment for hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. CDK4/6i plus ET is more effective than ET alone in this setting; however, the risk of grade 3-4 adverse events also increases. Approved agents in this class have similar efficacies, but important differences due to their structural and pharmacological properties. We review biomarkers and discuss determinants to inform a rational approach to therapy choice when selecting the most appropriate ET and CDK4/6i partners. We also identify subgroups that may benefit from specific ET-CDK4/6i combinations and discuss strategies to overcome resistance. This personalized approach aims to minimize treatment-related toxicities that may affect patient QoL and compliance, and ultimately therapy efficacy., Competing Interests: Conflict of interest LG reports Consulting or Advisory Role from Eli Lilly and Novartis, outside the submitted work. All other authors declare no potential conflict of interest., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
42. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.
- Author
-
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, and Dieci MV
- Abstract
Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline biopsy and residual disease (RD) in patients undergoing neoadjuvant treatment did not include the HER2-low-positive category. The aim of this study is to track the evolution of HER2-low-positive expression from primary BC to RD after neoadjuvant treatment. Patients undergoing neoadjuvant treatment with available baseline tumor tissue and matched samples of RD (in case of no pCR) were included. HER2-negative cases were sub-classified as HER2-0 or HER2-low-positive (IHC 1+ or 2+ and ISH negative). Four-hundred forty-six patients were included. Primary BC phenotype was: HR-positive/HER2-negative 23.5%, triple-negative (TN) 35%, HER2-positive 41.5%. HER2-low-positive cases were 55.6% of the HER2-negative cohort and were significantly enriched in the HR-positive/HER2-negative vs. TN subgroup (68.6% vs. 46.8%, p = 0.001 χ
2 test). In all, 35.3% of non-pCR patients (n = 291) had a HER2-low-positive expression on RD. The overall rate of HER2 expression discordance was 26.4%, mostly driven by HER2-negative cases converting either from (14.8%) or to (8.9%) HER2-low-positive phenotype. Among HR-positive/HER2-negative patients with HER2-low-positive expression on RD, 32.0% and 57.1% had an estimated high risk of relapse according to the residual proliferative cancer burden and CPS-EG score, respectively. In conclusion, HER2-low-positive expression showed high instability from primary BC to RD after neoadjuvant treatment. HER2-low-positive expression on RD may guide personalized adjuvant treatment for high-risk patients in the context of clinical trials with novel anti-HER2 antibody-drug conjugates., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
43. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.
- Author
-
Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, Urso L, Schiavi F, Pinato C, Magni G, Lo Mele M, De Salvo GL, Rosato A, and Conte P
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Female, Humans, Immunotherapy, Receptor, ErbB-2 metabolism, Tumor Microenvironment, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Neoadjuvant Therapy adverse effects
- Abstract
Purpose: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored., Patients and Methods: The neoadjuvant phase II GIADA trial (NCT04659551, EUDRACT 2016-004665-10) enrolled stage II-IIIA premenopausal patients with Luminal B (LumB)-like breast cancer (HR-positive/HER2-negative, Ki67 ≥ 20%, and/or histologic grade 3). Patients received: three 21-day cycles of epirubicin/cyclophosphamide followed by eight 14-day cycles of nivolumab, triptorelin started concomitantly to chemotherapy, and exemestane started concomitantly to nivolumab. Primary endpoint was pathologic complete response (pCR; ypT0/is, ypN0)., Results: A pCR was achieved by 7/43 patients [16.3%; 95% confidence interval (CI), 7.4-34.9]; the rate of residual cancer burden class 0-I was 25.6%. pCR rate was significantly higher for patients with PAM50 Basal breast cancer (4/8, 50%) as compared with other subtypes (LumA 9.1%; LumB 8.3%; P = 0.017). Tumor-infiltrating lymphocytes (TIL), immune-related gene-expression signatures, and specific immune cell subpopulations by multiplex immunofluorescence were significantly associated with pCR. A combined score of Basal subtype and TILs had an AUC of 0.95 (95% CI, 0.89-1.00) for pCR prediction. According to multiplex immunofluorescence, a switch to a more immune-activated tumor microenvironment occurred following exposure to anthracyclines. Most common grade ≥3 treatment-related adverse events (AE) during nivolumab were γ-glutamyltransferase (16.7%), alanine aminotransferase (16.7%), and aspartate aminotransferase (9.5%) increase. Most common immune-related AEs were endocrinopathies (all grades 1-2; including adrenal insufficiency, n = 1)., Conclusions: Luminal B-like breast cancers with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
44. Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer.
- Author
-
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, and Dieci MV
- Published
- 2021
- Full Text
- View/download PDF
45. Evolution of HER2-low expression from primary to recurrent breast cancer.
- Author
-
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, and Dieci MV
- Abstract
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. HER2 was evaluated according to ASCO/CAP recommendations in place at the time of diagnosis. A cutoff of >10% cells staining for HER2-positivity was applied. HER2-negative cases were sub-classified as HER2-low (IHC = 1 + /2+ and ISH not amplified), or HER2-0 (IHC-0). 547 patients were included. The proportion of HER2-low cases was 34.2% on the primary tumor and 37.3% on the relapse samples. Among HER2-negative cases, HER2-low status was more frequent in HR-positive vs triple-negative tumors (47.3% vs 35.4% on primary tumor samples, 53.8% vs 36.2% on relapse samples). The overall rate of HER2 discordance was 38.0%, mostly represented by HER2-0 switching to HER2-low (15%) and HER2-low switching to HER2-0 (14%). Among patients with a primary HER2-negative tumor, the rate of HER2 discordance was higher in HR-positive/HER2-negative vs triple-negative cases (45.5% vs 36.7% p = 0.170). This difference was mostly driven by cases switching from HER2-0 to HER2-low. HER2-low expression is highly unstable during disease evolution. Relapse biopsy in case of a primary HER2-0 tumor may open new therapeutic opportunities in a relevant proportion of patients., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
46. Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.
- Author
-
Di Liso E, Bottosso M, Lo Mele M, Tsvetkova V, Dieci MV, Miglietta F, Falci C, Faggioni G, Tasca G, Giorgi CA, Giarratano T, Mioranza E, Michieletto S, Saibene T, Dei Tos AP, Conte P, and Guarneri V
- Subjects
- Female, Humans, Mastectomy, Neoplasm Recurrence, Local surgery, Prognosis, Retrospective Studies, Breast Neoplasms diagnosis, Breast Neoplasms epidemiology, Breast Neoplasms therapy, Phyllodes Tumor diagnosis, Phyllodes Tumor surgery
- Abstract
Background: Phyllodes tumours (PTs) are rare fibroepithelial tumours accounting for <1% of all breast tumours. We assessed clinicopathological features and their prognostic effect in a single-institution patients' cohort., Methods: Patients diagnosed with PT between 2001 and 2018 at our institution were identified. Clinical, surgical and pathological features were collected. Phyllodes-related relapse was defined as locoregional or distant recurrence (contralateral excluded), whichever first., Results: A total of 166 patients were included: 115 with benign, 30 with borderline and 21 with malignant PTs. Features associated with malignant PT were younger age, larger T size, higher mitotic count, marked cytological atypia, stromal overgrowth, stromal hypercellularity, necrosis and heterologous differentiation (all p<0.01). The majority of patients with malignant PT underwent mastectomy (63.2% vs 3% of benign/borderline, p<0.001) and had negative surgical margins (83.3%). 4-year cumulative phyllodes-related relapse incidence was 7% for benign/borderline PT and 21.3% for malignant PT (p=0.107). In the entire cohort, marked cellular atypia and heterologous differentiation were associated with worse phyllodes-related relapse-free survival (HR 14.10, p=0.036 for marked vs mild atypia; HR 4.21, p=0.031 for heterologous differentiation present vs absent). For patients with benign PT, larger tumour size was associated with worse phyllodes-related relapse-free survival (HR 9.67, p=0.013 for T>5 cm vs T≤2 cm). Higher tumour-infiltrating lymphocytes (TILs) were associated with borderline and malignant PT (p=0.023); TILs were not associated with phyllodes-related relapse-free survival (HR 0.58, p=0.361 for TILs>2% vs≤2%). Overall, four patients died because of PT: three patients with malignant and one with borderline PT., Conclusions: Patients with malignant PT had increased rates of phyllodes-related relapse and phyllodes-related death. Cellular atypia and heterologous differentiation were poor prognostic factors in the entire cohort; large tumour size was associated with an increased risk of phyllodes-related relapse in benign PT., Competing Interests: Competing interests: MVD declares personal fees for consulting/advisory board from Eli Lilly, Celgene and Genomic Health. APDT declares personal fees for advisory boards/speaker’s bureau from PharaMAr, Lilly, Roche, Bayer and Pfizer. PFC reports grants (Institution) from Agenzia Italiana del Farmaco AIFA, Merck KGa and BMS; personal fees for consulting/advisory board from Novartis, EliLilly, AstraZeneca, Tesaro and Roche. VG reports grants (institution) and personal fees for consulting/advisor from Roche; personal fees for consulting/advisory relationship from Novartis and Eli Lilly. All the disclosures are outside the submitted work. All other authors declared no conflicts of interest., (© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2020
- Full Text
- View/download PDF
47. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
- Author
-
Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, and Guarneri V
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Female, Hormones, Humans, Neoadjuvant Therapy, Neoplasm, Residual drug therapy, Prognosis, Receptor, ErbB-2 genetics, Receptor, ErbB-2 therapeutic use, Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms drug therapy
- Abstract
Background: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long-term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared with RCB. However, no specific analysis in hormone-receptor-positive (HR+) human epidermal growth receptor 2-negative (HER2-) BC is available so far., Materials and Methods: A cohort of 130 patients with HR+/HER2- BC who underwent NACT between 2000 and 2014 was included. Archival surgical specimens were evaluated for RCB. RPCB was calculated by combining RCB and Ki67 as previously described. Patients were categorized in four RCB and RPCB categories (pathological complete response and tertiles). Disease-free survival (DFS) and overall survival (OS) estimates were determined by Kaplan-Meier analysis and compared using the log-rank test. Overall change of χ
2 and c-indexes were used to compare the performance of the prognostic models., Results: RPCB was calculated for 85 patients. After a median follow up of 8.5 years, RCB was associated with OS (p = .048) but not with DFS (p = .152); RPCB was instead significantly associated with both DFS and OS (p = .034 and p < .001, respectively). In terms of OS, RPCB provided a significant amount of prognostic information beyond RCB (∆χ2 5.73, p < .001). In addition, c-index for OS prediction was significantly higher for RPCB as compared with RCB (0.79 vs. 0.61, p = .03)., Conclusion: This is the first study evaluating RPCB in patients with HR+/HER2- BC treated with NACT. In this independent cohort, RPCB was a strong predictor of DFS and OS. The better performance of RPCB versus RCB was in part due to the ability of RPCB to discriminate a subgroup of patients with a particularly worse prognosis after NACT, who may be candidates for clinical trials evaluating novel adjuvant strategies., Implications for Practice: The present work validated residual proliferative cancer burden (RPCB) as a strong predictor of long-term outcome in patients with hormone receptor-positive human epidermal growth receptor 2-negative (HR+/HER2-) breast cancer (BC) treated with neoadjuvant chemotherapy. In addition, results from the present study suggest RPCB as a promising tool to identify patients with HR+/HER2- BC who might potentially benefit from the inclusion in clinical trials evaluating novel or escalated postneoadjuvant treatment strategies because it allowed to discriminate a subgroup of patients with particularly poor prognosis despite having received subsequent endocrine therapy in the adjuvant setting., (© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.)- Published
- 2020
- Full Text
- View/download PDF
48. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
- Author
-
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, and Prat A
- Abstract
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally, ERBB2 expression was explored in 392 BCs from an in-house dataset, 368 primary BCs from The Cancer Genome Atlas (TCGA) dataset and 10,071 tumors representing 33 cancer types from the PanCancer TCGA dataset. High ERBB2 mRNA was found associated with better response and progression-free survival in the metastatic setting and higher rates of pathological complete response in the neoadjuvant setting. ERBB2 expression also correlated with in vitro response to T-DM1. Finally, our assay identified 0.20-8.41% of tumors across 15 cancer types as ERBB2 -high, including gastric and esophagus adenocarcinomas, urothelial carcinoma, cervical squamous carcinoma and pancreatic cancer. In particular, we identified high ERBB2 mRNA in a patient with HER2+ advanced gastric cancer who achieved a long-lasting partial response to T-DM1. Our study demonstrates that the heterogeneity in response to T-DM1 is partly explained by ERBB2 levels and provides a clinically applicable assay to be tested in future clinical trials of breast cancer and other cancer types.
- Published
- 2020
- Full Text
- View/download PDF
49. Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study.
- Author
-
Giarratano T, Frezzini S, Zanocco M, Giorgi CA, Mioranza E, Miglietta F, Griguolo G, Falci C, Faggioni G, Tasca G, Di Liso E, Vernaci G, Menichetti A, Mantiero M, Grosso D, Guarneri V, and Dieci MV
- Subjects
- Alopecia chemically induced, Alopecia prevention & control, Antineoplastic Combined Chemotherapy Protocols adverse effects, Female, Humans, Prospective Studies, Quality of Life, Scalp, Breast Neoplasms drug therapy, Hypothermia, Induced
- Abstract
Chemotherapy-induced alopecia (CIA) affects the majority of patients receiving chemotherapy (CT) for early breast cancer. It is a highly distressing side effect of CT, with psychological and social impact. Primary aim of the present analysis was to assess the efficacy of scalp cooling with DigniCap® in preventing CIA. Success rate was defined as patients' self-reported hair loss <50% according to Dean scale. In this analysis, we reported success rate at 3 weeks after the first CT course and at 3 weeks after the last CT course. Secondary endpoints included self-reported tolerability and patients' judgment on scalp cooling performance. Consecutive early breast cancer patients admitted to Istituto Oncologico Veneto who were recommended to receive neoadjuvant or adjuvant CT, were eligible to undergo scalp cooling during the CT administration within this study. 135 patients were included: 74% received adjuvant CT and 26% neoadjuvant CT (P < .001). The type of CT was: docetaxel-cyclophosphamide (26%), paclitaxel (23%), epirubicin-cyclophosphamide followed by paclitaxel (32%), and paclitaxel followed by epirubicincyclophosphamide (19%). The rate of success in preventing alopecia was 77% (104/135) at 3 weeks from the start of CT and 60% (81/135) at 3 weeks from the end of treatment. Higher success rates were reported in non-anthracycline (71%) compared to anthracycline-containing CT regimens (54%; P < 0.001). Premature discontinuation of scalp cooling was reported in 29/135 patients (21.5%), including withdrawal for alopecia (16/29), for low scalp cooling tolerability (8/29) or both (5/29). Scalp cooling was generally well tolerated. These results overall suggest that the use of scalp cooling is effective in preventing alopecia in the majority of early breast cancer patients receiving neoadjuvant or adjuvant CT, especially for patients undergoing a taxane-based non-anthracycline regimen., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
50. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
- Author
-
Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, and Conte P
- Subjects
- Adult, Aged, Aged, 80 and over, Biological Assay, Biomarkers, Tumor metabolism, Breast Neoplasms genetics, Breast Neoplasms pathology, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast genetics, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular drug therapy, Carcinoma, Lobular genetics, Carcinoma, Lobular pathology, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Italy, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Prognosis, Prospective Studies, Receptors, Progesterone metabolism, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Breast Neoplasms drug therapy, Clinical Decision-Making, Gene Expression Profiling, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism
- Abstract
Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer., Materials and Methods: Nine centers participated. Physicians used the RS test whenever unsure about adjuvant treatment recommendation for patients with estrogen receptor-positive/human epidermal growth receptor 2-negative, T1-T3, N0-N1 early breast cancer. Pre-RS and post-RS treatment recommendations were collected., Results: A total of 251 patients were included. N0 patients (61%) showed higher grade ( p < .001) and higher Ki67 ( p = .001) and were more frequently progesterone receptor negative ( p = .012) as compared with N1 patients. RS results were as follows: <11, n = 63 (25.1%); 11-25, n = 143 (57%); and ≥26, n = 45 (17.9%). Higher RS was found in N0 vs. N1 patients ( p = .001) and in cases of G3 ( p < .001) and higher Ki67 ( p < .001). The rate of change in treatment decision was 30% ( n = 75), mostly from chemotherapy (CT) plus hormone therapy (CT + HT) to hormone therapy (HT; 76%, n = 57/75). The proportion of patients recommended to CT + HT was significantly reduced from pre-RS to post-RS (52% to 36%, p < .0001). CT use reduction was more evident for N1 patients (55% to 27%) than for N0 patients (50% to 42%) and was observed only in cases of RS ≤17., Conclusion: Physicians predominantly used the 21-gene assay in N0 patients with a more aggressive biology or in N1 patients showing more indolent biology. In this selected patient population, the use of RS testing led to a 30% rate of change in treatment decision. In the N1 patient subgroup, the use of RS testing contributed to reduce CT use by more than half., Implications for Practice: This study shows that, even in a context in which physicians recommend a high proportion of patients to endocrine treatment alone before knowing the results of the Recurrence Score (RS) assay, the use of the RS test, whenever uncertainty regarding adjuvant treatment recommendation is present, significantly contributes in further reducing the use of chemotherapy, especially for N1 patients., Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article., (© AlphaMed Press 2019.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.